第 1 到 11 筆結果,共 11 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2022 | Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma | Chi-ya Shen; Chang, Wen-Hsin; Chen, Yi-Ju; Weng, Chia-Wei; Regmi, Prabha; Kier, Mickiela K K; KANG-YI SU ; Chang, Gee-Chen; JIN-SHING CHEN ; Chen, Yu-Ju; SUNG-LIANG YU | Journal of proteome research | 4 | 0 | |
2 | 2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
3 | 2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
4 | 2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
5 | 2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
6 | 2022 | Genetic Deletion of HLJ1 Does Not Affect Blood Coagulation in Mice | Hsu, Man-Chen; Luo, Wei-Jia; Guo, Bei-Chia; Chen, Chia-Hui; Hu, Po-An; Tsai, Yi-Hsuan; KANG-YI SU ; TZONG-SHYUAN LEE | International journal of molecular sciences | 0 | 0 | |
7 | 2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
8 | 2022 | HLJ1 amplifies endotoxin-induced sepsis severity by promoting IL-12 heterodimerization in macrophages | Luo, Wei-Jia; SUNG-LIANG YU ; Chang, Chia-Ching; Chien, Min-Hui; Chang, Ya-Ling; Liao, Keng-Mao; Lin, Pei-Chun; KUEI-PIN CHUNG ; YA-HUI CHUANG ; Chen, Jeremy J W; PAN-CHYR YANG ; KANG-YI SU | eLife | 7 | 3 | |
9 | 2022 | Novel Genetic Prognostic Signature for Lung Adenocarcinoma Identified by Differences in Gene Expression Profiles of Low- and High-Grade Histological Subtypes | Chang, Chia-Ching; MIN-SHU HSIEH ; MONG-WEI LIN ; Lee, Yi-Hsuan; Hsiao, Yi-Jing; KANG-YI SU ; Su, Te-Jen; SUNG-LIANG YU ; JIN-SHING CHEN | Biomolecules | 3 | 4 | |
10 | 2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |
11 | 2022 | Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis | Chang, Hui-Lan; KANG-YI SU ; Goodman, Steven D; WERN-CHERNG CHENG ; LIANG-IN LIN ; YA-CHIEN YANG ; SUI-YUAN CHANG ; WOEI-HORNG FANG | Journal of visualized experiments : JoVE | 1 | 1 |